PET brain imaging of the serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor has been widely used in clinical studies. Currently, only a few well-validated radiolabeled antago'/> Radiosynthesis and Preclinical Evaluation of 18F-F13714 as a Fluorinated 5-HT1A Receptor Agonist Radioligand for PET Neuroimaging
首页> 外文期刊>The Journal of Nuclear Medicine >Radiosynthesis and Preclinical Evaluation of 18F-F13714 as a Fluorinated 5-HT1A Receptor Agonist Radioligand for PET Neuroimaging
【24h】

Radiosynthesis and Preclinical Evaluation of 18F-F13714 as a Fluorinated 5-HT1A Receptor Agonist Radioligand for PET Neuroimaging

机译:PET成像的18F-F13714氟化5-HT1A受体激动剂放射性配体的放射合成和临床前评价

获取原文
           

摘要

id="p-2">PET brain imaging of the serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor has been widely used in clinical studies. Currently, only a few well-validated radiolabeled antagonist tracers are available for in vivo imaging of this central receptor. 5-HT1A receptors exist in high- and low-affinity states, depending on their coupling to G proteins. Agonists bind preferentially to receptors in the high-affinity state and thereby could provide a measure of functional 5-HT1A receptors. Therefore, it is of great interest to develop an 18F-labeled full agonist 5-HT1A receptor radiotracer. In this study, we radiolabeled the high-affinity 5-HT1A receptor agonist 18F-F13714 and investigated its potential as a PET tracer. >Methods: F13714 nitro precursor was synthesized and radiolabeled via a fluoronucleophilic substitution. In vitro binding assays were performed using established protocols. Radiopharmacologic evaluations included in vitro autoradiography in rat brain and PET scans on anesthetized cats. >Results: The chemical and radiochemical purities of 18F-F13714 were greater than 98%. F13714 has a high affinity (0.1 nM) and selectivity for 5-HT1A receptors. In vitro 18F-F13714 binding in rats was consistent with the known 5-HT1A receptors distribution (hippocampus and cortical areas) and was particularly high in the dorsal raphe. In vitro binding of 18F-F13714 was blocked in a dose-dependent fashion by WAY100635, the prototypical 5-HT1A antagonist, and by the endogenous agonist, serotonin (5-HT). Addition of Gpp(NH)p also inhibited in vitro 18F-F13714 binding, consistent with a preferential binding of the compound to G-protein-coupled receptors. Ex vivo tissue measurements in rat revealed an absence of brain radioactive metabolites. In vivo studies showed that the radiotracer entered the cat brain readily and displayed a preferential labeling of 5-HT1A receptors located in cingulate cortex. In vivo labeling was prevented by preinjection of WAY100635. >Conclusion: 18F-F13714 is a radiofluorinated agonist that presents suitable characteristics for probing the high-affinity states of the 5-HT1A receptors in vitro and in vivo. Thus, it is a promising tool for investigation of 5-HT1A agonist binding in the living human brain.
机译:id =“ p-2”> 5-羟色胺1A(5-羟色胺1A [5-HT 1A ])的PET脑成像已在临床研究中广泛使用。目前,只有少数经过充分验证的放射性标记的拮抗剂示踪剂可用于该中枢受体的体内成像。 5-HT 1A 受体以高亲和力和低亲和力状态存在,具体取决于它们与G蛋白的偶联情况。激动剂优先与高亲和力受体结合,从而可以提供功能性5-HT 1A 受体的量度。因此,开发一种 18 F标记的全激动剂5-HT 1A 受体放射性示踪剂非常重要。在这项研究中,我们对高亲和力的5-HT 1A 受体激动剂 18 F-F13714进行了放射性标记,并研究了其作为PET示踪剂的潜力。 >方法:合成了F13714硝基前体,并通过氟亲核取代进行了放射性标记。使用建立的方案进行体外结合测定。放射药理学评估包括大鼠脑部体外放射自显影和麻醉猫的PET扫描。 >结果: 18 F-F13714的化学和放射化学纯度大于98%。 F13714对5-HT 1A 受体具有高亲和力(0.1 nM)和选择性。大鼠体内 18 F-F13714的结合与已知的5-HT 1A 受体分布(海马和皮层区域)一致,在背侧缝隙中特别高。典型的5-HT 1A 拮抗剂WAY100635和内源性激动剂5-羟色胺以剂量依赖的方式阻断 18 F-F13714的体外结合(5)。 -H T)。 Gpp(NH)p的加入还抑制了 18 F-F13714的体外结合,这与该化合物与G蛋白偶联受体的优先结合相一致。大鼠的离体组织测量显示不存在脑放射性代谢产物。体内研究表明,放射性示踪剂很容易进入猫脑,并在扣带回皮层中显示了5-HT 1A 受体的优先标记。通过预先注射WAY100635可防止体内标记。 >结论: 18 F-F13714是一种放射性氟化激动剂,具有合适的特征来探测5-HT 1A 受体的高亲和力状态。体外和体内。因此,它是研究人脑中5-HT 1A 激动剂结合的有前途的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号